Join us as we explore the innovations that defined 2025—and what they mean for the future of the field.

PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...

While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Use this brand-new eBook from Cytiva to learn more about the oligonucleotide market as a whole and about the full workflow solutions available today. We hope you enjoy it!

As of Tuesday, December 30, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 9.99%, which has investors questioning if this is right time to sell.

As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...

CAMP4 will apply its RAP Platform® to generate antisense oligonucleotide candidates, while GSK will lead development and ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

AusperBio completes patient enrollment in phase III AUSHINE study of AHB-137 for chronic hepatitis B: San Francisco Tuesday, December 23, 2025, 15:00 Hrs [IST] AusperBio Therapeut ...

Final results from the VALOR trial and its open-label extension demonstrated the clinical benefit of tofersen in adults with ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...